6. Rodgers JM, Robinson AP, Miller SD. Strategies for protecting
oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med.
2013; 16(86): 53-63.
7. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus
regenerative medicine. J Cell Physiol. 2007; 213(2): 341-347.
8. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review:
mesenchymal stem cells: their phenotype, differentiation capacity, immunological
features, and potential for homing. Stem Cells. 2007; 25(11): 2739-2749.
9. Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W. Mesenchymal stem
cells and induced pluripotent stem cells as therapies for multiple sclerosis. Int J
Mol Sci. 2015; 16(5): 9283-9302. doi: 10.3390/ijms16059283.
10. Al Jumah MA, Abumaree MH. The immunomodulatory and
neuroprotective effects of mesenchymal stem cells (MSCs) in experimental
autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). Int J
Mol Sci. 2012; 13(7): 9298-9331. doi: 10.3390/ijms13079298.
11. Payne NL, Sun G, McDonald C, et al. Distinct immunomodulatory and
migratory mechanisms underpin the therapeutic potential of human mesenchymal
stem cells in autoimmune demyelination. Cell Transplant. 2013; 22(8): 1409-
1425. doi: 10.3727/096368912X657620.
12. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell
transplantation for progressive multiple sclerosis: Failure of a total body
irradiation–based conditioning regimen to prevent disease progression in patients
with high disability scores. Blood. 2003 Oct 1; 102(7): 2373-8.
13. Connick P, Kolappan M, Patani R, et al. The mesenchymal stem cells in
multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics:
An open-label pre-test: Post-test study with blinded outcome assessments. Trials.
2011 Mar 2; 12:62. doi: 10.1186/1745-6215-12-62.
14. Ardeshiry Lajimi A, Hagh MF, Saki N, Mortaz E, Soleimani M, Rahim
F. Feasibility of cell therapy in multiple sclerosis: a systematic review of 83
studies. Int J Hematol Oncol Stem Cell Res. 2013; 7(1): 15-33.
